Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?
Cancer · 2023
DOI: 10.1002/cncr.34769 ↗Kurz gefasst
Editorial in der Zeitschrift Cancer, 2023. Verfasst von Diandra N Ayala-Peacock und 1 weiteren Autor:innen. Beteiligte Einrichtung: Duke Cancer Institute, Raleigh and Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Radiation Injuries, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Evaluating a recent prospective trial of active bone marrow sparing defined by 99 mTc‐single‐photon emission computed tomography imaging in the landscape of the existing literature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke Cancer Institute, Raleigh and Durham, North Carolina, USA.
- Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Diandra N Ayala-Peacock, Junzo P Chino
Zitieren
APA
Ayala-Peacock, D. N., & Chino, J. P. (2023). Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?. Cancer. https://doi.org/10.1002/cncr.34769
Vancouver
Ayala-Peacock DN, Chino JP. Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?. Cancer. 2023. doi:10.1002/cncr.34769
BibTeX
@article{AyalaPeacock2023,
author = {Ayala-Peacock, Diandra N and Chino, Junzo P},
title = {Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34769}
}
EUVIMED